At the tip of an iceberg: Prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring

Biological Psychiatry

Volumn 79, Issue 7, 2016, Pages e33-e45

  Alpár, Alán ^a,b   Di Marzo, Vincenzo ^c   Harkany, Tibor ^d,e  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c CNR Consiglio Nazionale delle Ricerche   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Medical University of Vienna   (Austria)

Author keywords

Epilepsy; Marijuana; Psychosis; Schizophrenia; Skunk; Stratification

Indexed keywords

4 AMINOBUTYRIC ACID; CANNABINOID RECEPTOR; CANNABIS; ENDOCANNABINOID; OPIATE; STREET DRUG;

BEHAVIOR DISORDER; BRAIN DEVELOPMENT; BRAIN MATURATION; CANNABIS USE; DEPRESSION; DISEASE PREDISPOSITION; DRUG EXPOSURE; ENVIRONMENTAL STRESS; EPILEPSY; FETAL BRAIN; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; PERINATAL PERIOD; PREGNANCY; PRENATAL PERIOD; PRIORITY JOURNAL; PROGENY; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ADVERSE EFFECTS; ANIMAL; BRAIN; CANNABIS SMOKING; CELL DIFFERENTIATION; DRUG EFFECTS; FEMALE; FETUS DEVELOPMENT; METABOLISM; PATHOLOGY; PRENATAL EXPOSURE;

ANIMALS; BRAIN; CELL DIFFERENTIATION; ENDOCANNABINOIDS; FEMALE; FETAL DEVELOPMENT; HUMANS; MARIJUANA SMOKING; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SIGNAL TRANSDUCTION; STREET DRUGS;

EID: 84949294678     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2015.09.009     Document Type: Review

References (191)

1. Rakic P (1990): Principles of neural cell migration. Experientia 46: 882-891.
2. Rakic P (2002): Neurogenesis in adult primate neocortex: An evaluation of the evidence. Nat Rev Neurosci 3:65-71.
3. Rakic P (2003): Developmental and evolutionary adaptations of cortical radial glia. Cereb Cortex 13:541-549.
4. Decorte T, Potter GR (2015): The globalisation of cannabis cultivation: A growing challenge. Int J Drug Policy 26:221-225.
5. Potter GR, Barratt MJ, Malm A, Bouchard M, Blok T, Christensen AS, et al. (2015): Global patterns of domestic cannabis cultivation: Sample characteristics and patterns of growing across eleven countries. Int J Drug Policy 26:226-237.
6. National Institute on Drug Abuse (2005): NIDA Monograph Series: Marijuana Abuse. Rockville, MD: National Institute on Drug Abuse.
7. Substance Abuse and Mental Health Services Administration (2011): Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration.
8. Volkow ND, Baler RD, Compton WM, Weiss SR (2014): Adverse health effects of marijuana use. N Engl J Med 370:2219-2227.
9. European Monitoring Centre for Drugs and Drug Addiction (2012): Legal topic overviews: Possession of cannabis for personal use. EMCDDA. Available at: http://www.emcdda.europa.eu/legal-topic-o verviews/cannabis-possession-for-personal-use. Accessed October 23, 2015.
10. European Monitoring Centre for Drugs and Drug Addiction (2013): Synthetic Cannabinoids in Europe. EMCDDA. Available at: http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids. Accessed October 23, 2015.
11. Fried PA, Smith AM (2001): A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol 23:1-11.
12. Campolongo P, Trezza V, Ratano P, Palmery M, Cuomo V (2011): Developmental consequences of perinatal cannabis exposure: Behavioral and neuroendocrine effects in adult rodents. Psychopharmacology (Berl) 214:5-15.
13. Vorhees CV (1989): Concepts in teratology and developmental toxicology derived from animal research. Ann N Y Acad Sci 562:31-41.
14. Calvigioni D, Hurd YL, Harkany T, Keimpema E (2014): Neuronal substrates and functional consequences of prenatal cannabis exposure. Eur Child Adolesc Psychiatry 23:931-941.
15. Keimpema E, Calvigioni D, Harkany T (2013): Endocannabinoid signals in the developmental programming of delayed-onset neuropsychiatric and metabolic illnesses. Biochem Soc Trans 41: 1569-1576.
16. Psychoyos D, Vinod KY (2013): Marijuana, Spice 'herbal high', and early neural development: Implications for rescheduling and legalization. Drug Test Anal 5:27-45.
17. Hall W (2009): The adverse health effects of cannabis use: What are they, and what are their implications for policy? Int J Drug Policy 20: 458-466.
18. Boycott R (1997): The time is right to decriminalise cannabis. The Independent on Sunday. September 28, 1997:2:1.
19. Hayes JS, Lampart R, Dreher MC, Morgan L (1991): Five-year followup of rural Jamaican children whose mothers used marijuana during pregnancy. West Indian Med J 40:120-123.
20. Grotenhermen F (2007): The toxicology of cannabis and cannabis prohibition. Chem Biodivers 4:1744-1769.
21. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007): Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370: 319-328.
22. Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. (2014): Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 40: 1509-1517.
23. Iseger TA, Bossong MG (2015): A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162: 153-161.
24. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS (2012): Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 367:3364-3378.
25. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. (2014): Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55: 791-802.
26. Weiland BJ, Thayer RE, Depue BE, Sabbineni A, Bryan AD, Hutchison KE (2015): Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. J Neurosci 35:1505-1512.
27. Hurd YL, Wang X, Anderson V, Beck O, Minkoff H, Dow-Edwards D (2005): Marijuana impairs growth in mid-gestation fetuses. Neurotoxicol Teratol 27:221-229.
28. Day NL, Richardson GA (1991): Prenatal marijuana use: Epidemiology, methodologic issues, and infant outcome. Clin Perinatol 18:77-91.
29. Linn S, Schoenbaum SC, Monson RR, Rosner R, Stubblefield PC, Ryan KJ (1983): The association of marijuana use with outcome of pregnancy. Am J Public Health 73:1161-1164.
30. Hutchings DE, Martin BR, Gamagaris Z, Miller N, Fico T (1989): Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci 44:697-701.
31. Perez-Reyes M, Wall ME (1982): Presence of delta9- tetrahydrocannabinol in human milk. N Engl J Med 307:819-820.
32. Astley SJ, Little RE (1990): Maternal marijuana use during lactation and infant development at one year. Neurotoxicol Teratol 12: 161-168.
33. Oliet SH, Baimoukhametova DV, Piet R, Bains JS (2007): Retrograde regulation of GABA transmission by the tonic release of oxytocin and endocannabinoids governs postsynaptic firing. J Neurosci 27: 1325-1333.
34. Fonseca BM, Correia-da-Silva G, Taylor AH, Lam PM, Marczylo TH, Bell SC, et al. (2010): The endocannabinoid 2-arachidonoylglycerol (2-AG) and metabolizing enzymes during rat fetoplacental development: A role in uterine remodelling. Int J Biochem Cell Biol 42: 1884-1892.
35. Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R (2001): Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 419:207-214.
36. Tortoriello G, Morris CV, Alpár A, Fuzik J, Shirran SL, Calvigioni D, et al. (2014): Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J 33:668-685.
37. Tree KC, Scotto di Perretolo M, Peyronnet J, Cayetanot F (2014): In utero cannabinoid exposure alters breathing and the response to hypoxia in newborn mice. Eur J Neurosci 40:2196-2204.
38. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, et al. (2009): The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106:16511-16516.
39. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990): Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
40. Galve-Roperh I, Aguado T, Rueda D, Velasco G, Guzman M (2006): Endocannabinoids: A new family of lipid mediators involved in the regulation of neural cell development. Curr Pharm Des 12: 2319-2325.
41. Munro S, Thomas KL, Abu-Shaar M (1993): Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
42. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008): GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105:2699-2704.
43. O'Sullivan SE (2007): Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152:576-582.
44. De Petrocellis L, Di Marzo V (2010): Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: Focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 5:103-121.
45. Morgan NH, Stanford IM, Woodhall GL (2009): Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology 57: 356-368.
46. Duff G, Argaw A, Cecyre B, Cherif H, Tea N, Zabouri N, et al. (2013): Cannabinoid receptor CB2 modulates axon guidance. PLoS One 8: e70849.
47. El Andaloussi-Lilja J, Lundqvist J, Forsby A (2009): TRPV1 expression and activity during retinoic acid-induced neuronal differentiation. Neurochem Int 55:768-774.
48. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (1992): Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
49. Stella N, Schweitzer P, Piomelli D (1997): A second endogenous cannabinoid that modulates long-term potentiation. Nature 388: 773-778.
50. Gokoh M, Kishimoto S, Oka S, Mori M, Waku K, Ishima Y, Sugiura T (2005): 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. Biochem J 386:583-589.
51. Katona I, Sperlágh B, Maglóczky Z, Sántha E, Kofalvi A, Czirjak S, et al. (2000): GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100:797-804.
52. Katona I, Sperlágh B, Sík A, Kofalvi A, Vizi ES, Mackie K, Freund TF (1999): Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544-4558.
53. Katona I, Urbán GM, Wallace M, Ledent C, Jung KM, Piomelli D, et al. (2006): Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26:5628-5637.
54. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009): Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309-380.
55. Piet R, Garenne A, Farrugia F, Le Masson G, Marsicano G, Chavis P, Manzoni OJ (2011): State-dependent, bidirectional modulation of neural network activity by endocannabinoids. J Neurosci 31: 16591-16596.
56. Lastres-Becker I, De Miguel R, Fernandez-Ruiz JJ (2003): The endocannabinoid system and Huntington's disease. Curr Drug Targets CNS Neurol Disord 2:335-347.
57. Laviolette SR, Grace AA (2006): The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: Implications for schizophrenia and addiction. Cell Mol Life Sci 63: 1597-1613.
58. D'Addario C, Micioni Di Bonaventura MV, Pucci M, Romano A, Gaetani S, Ciccocioppo R, et al. (2014): Endocannabinoid signaling and food addiction. Neurosci Biobehav Rev 47:203-224.
59. Katona I, Freund TF (2008): Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14:923-930.
60. Leterrier C, Laine J, Darmon M, Boudin H, Rossier J, Lenkei Z (2006): Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. J Neurosci 26: 3141-3153.
61. De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, et al. (2011): Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163: 1479-1494.
62. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG (2005): Evidence that the plant cannabinoid Delta9- tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146:917-926.
63. McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015): Are cannabidiol and Delta(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172:737-753.
64. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. (2001): Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845-852.
65. Berrendero F, Garcia-Gil L, Hernandez ML, Romero J, Cebeira M, de Miguel R, et al. (1998): Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development 125: 3179-3188.
66. Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K (2007): The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28:83-92.
67. Maccarrone M, Guzman M, Mackie K, Doherty P, Harkany T (2014): Programming of neural cells by (endo)cannabinoids: From physiological rules to emerging therapies. Nat Rev Neurosci 15:786-801.
68. Fernandez-Ruiz JJ, Berrendero F, Hernandez ML, Romero J, Ramos JA (1999): Role of endocannabinoids in brain development. Life Sci 65:725-736.
69. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. (2003): Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163:463-468.
70. Simon GM, Cravatt BF (2008): Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho- N-acyl ethanolamine precursors in mouse brain. J Biol Chem 283: 9341-9349.
71. Keimpema E, Barabas K, Morozov YM, Tortoriello G, Torii M, Cameron G, et al. (2010): Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2- arachidonoyl glycerol signaling during axonal pathfinding. J Neurosci 30:13992-14007.
72. Talens-Visconti R, Sanchez-Vera I, Kostic J, Perez-Arago MA, Erceg S, Stojkovic M, Guerri C (2011): Neural differentiation from human embryonic stem cells as a tool to study early brain development and the neuroteratogenic effects of ethanol. Stem Cells Dev 20:327-339.
73. Dinh TP, Freund TF, Piomelli D (2002): A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121: 149-158.
74. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996): Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87.
75. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. (2003): CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88.
76. Jin K, Xie L, Kim SH, Parmentier-Batteur S, Sun Y, Mao XO, et al. (2004): Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol 66:204-208.
77. Guzman M, Sanchez C, Galve-Roperh I (2001): Control of the cell survival/death decision by cannabinoids. J Mol Med (Berl) 78: 613-625.
78. Rueda D, Navarro B, Martinez-Serrano A, Guzman M, Galve-Roperh I (2002): The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J Biol Chem 277:46645-46650.
79. Alpár A, Tortoriello G, Calvigioni D, Niphakis MJ, Milenkovic I, Bakker J, et al. (2014): Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. Nat Commun 5:4421.
80. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, et al. (2007): Hardwiring the brain: Endocannabinoids shape neuronal connectivity. Science 316:1212-1216.
81. Vitalis T, Laine J, Simon A, Roland A, Leterrier C, Lenkei Z (2008): The type 1 cannabinoid receptor is highly expressed in embryonic cortical projection neurons and negatively regulates neurite growth in vitro. Eur J Neurosci 28:1705-1718.
82. Rodriguez de Fonseca F, Cebeira M, Fernandez-Ruiz JJ, Navarro M, Ramos JA (1991): Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons. Neuroscience 43:713-723.
83. Mirmiran M, Swaab DF (1987): Influence of drugs on brain neurotransmitters and behavioral states during development. Dev Pharmacol Ther 10:377-384.
84. Spano MS, Ellgren M, Wang X, Hurd YL (2007): Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol Psychiatry 61:554-563.
85. DiNieri JA, Wang X, Szutorisz H, Spano SM, Kaur J, Casaccia P, et al. (2011): Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol Psychiatry 70:763-769.
86. Gardner E (1992): Cannabinoid interaction with brain reward systems - The neurobiological basis of cannabinoid abuse. In: Bartke A, editor. Neurobiology and Neurophysiology of Cannabinoids Biochemistry and Physiology of Substance Abuse. Boca Raton, FL: CRC Press, 275-335.
87. Levenson SF (1990): Effects of delta-tetrahydrocannabinol on ventral tegmental A10 dopamine neurons in the rat. Soc Neurosci Abstr 16: 1100.
88. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990): Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 102:156-162.
89. Navarro M, de Miguel R, Rodriguez de Fonseca F, Ramos JA, Fernandez-Ruiz JJ (1996): Perinatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats. Behav Brain Res 75:91-98.
90. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990): Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932-1936.
91. Mailleux P, Vanderhaeghen JJ (1992): Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci Lett 148:173-176.
92. Wang X, Dow-Edwards D, Keller E, Hurd YL (2003): Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience 118:681-694.
93. Wang X, Dow-Edwards D, Anderson V, Minkoff H, Hurd YL (2004): In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry 56:909-915.
94. Goldschmidt L, Day NL, Richardson GA (2000): Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol 22:325-336.
95. Leech SL, Richardson GA, Goldschmidt L, Day NL (1999): Prenatal substance exposure: Effects on attention and impulsivity of 6-yearolds. Neurotoxicol Teratol 21:109-118.
96. Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L (2002): Prenatal alcohol and marijuana exposure: Effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol 24:309-320.
97. Whalen PJ, Shin LM, Somerville LH, McLean AA, Kim H (2002): Functional neuroimaging studies of the amygdala in depression. Semin Clin Neuropsychiatry 7:234-242.
98. Gray KA, Day NL, Leech S, Richardson GA (2005): Prenatal marijuana exposure: Effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol 27:439-448.
99. Chen K, Kandel DB (1998): Predictors of cessation of marijuana use: An event history analysis. Drug Alcohol Depend 50:109-121.
100. Navarro M, Rubio P, de Fonseca FR (1995): Behavioural consequences of maternal exposure to natural cannabinoids in rats. Psychopharmacology (Berl) 122:1-14.
101. Navarro M, Rodriguez de Fonseca F, Hernandez ML, Ramos JA, Fernandez-Ruiz JJ (1994): Motor behavior and nigrostriatal dopaminergic activity in adult rats perinatally exposed to cannabinoids. Pharmacol Biochem Behav 47:47-58.
102. Corchero J, Manzanares J, Fuentes JA (2004): Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 16: 159-172.
103. Mohammadi M, Nasehi M, Zarrindast MR (2015): Modulation of the effects of the cannabinoid agonist, ACPA, on spatial and non-spatial novelty detection in mice by dopamine D1 receptor drugs infused into the basolateral amygdala. Behav Brain Res 280: 36-44.
104. Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ, et al. (2014): Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A 111:E5007-E5015.
105. Bodnar RJ, Klein GE (2004): Endogenous opiates and behavior: 2003. Peptides 25:2205-2256.
106. Herz A (1998): Opioid reward mechanisms: A key role in drug abuse? Can J Physiol Pharmacol 76:252-258.
107. Vigano D, Rubino T, Parolaro D (2005): Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 81:360-368.
108. Ellgren M, Spano SM, Hurd YL (2007): Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32:607-615.
109. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R (2002): Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22: 1146-1154.
110. Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP (2001): Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: Reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci, (13), 1816-1824.
111. Solinas M, Zangen A, Thiriet N, Goldberg SR (2004): Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol. Eur J Neurosci 19: 3183-3192.
112. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. (1999): Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404.
113. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, Fratta W (2001): Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 118:61-65.
114. De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN (2003): Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) 168:164-169.
115. Wang X, Dow-Edwards D, Anderson V, Minkoff H, Hurd YL (2006): Discrete opioid gene expression impairment in the human fetal brain associated with maternal marijuana use. Pharmacogenomics J 6: 255-264.
116. Skoubis PD, Lam HA, Shoblock J, Narayanan S, Maidment NT (2005): Endogenous enkephalins, not endorphins, modulate basal hedonic state in mice. Eur J Neurosci 21:1379-1384.
117. Kelley AE (2004): Ventral striatal control of appetitive motivation: Role in ingestive behavior and reward-related learning. Neurosci Biobehav Rev 27:765-776.
118. Goldschmidt L, Richardson GA, Cornelius MD, Day NL (2004): Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol 26:521-532.
119. Fried PA (1996): Behavioral outcomes in preschool and school-age children exposed prenatally to marijuana: A review and speculative interpretation. NIDA Res Monogr 164:242-260.
120. Kandel DB (2003): Does marijuana use cause the use of other drugs? JAMA 289:482-483.
121. Bandstra ES, Morrow CE, Anthony JC, Accornero VH, Fried PA (2001): Longitudinal investigation of task persistence and sustained attention in children with prenatal cocaine exposure. Neurotoxicol Teratol 23:545-559.
122. Gonzalez S, Valenti M, de Miguel R, Fezza F, Fernandez-Ruiz J, Di Marzo V, Ramos JA (2004): Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. Br J Pharmacol 143:455-464.
123. Ortiz S, Oliva JM, Perez-Rial S, Palomo T, Manzanares J (2004): Chronic ethanol consumption regulates cannabinoid CB1 receptor gene expression in selected regions of rat brain. Alcohol Alcohol 39: 88-92.
124. Pietrzak B, Dunaj A, Piatkowska K (2011): [The role of the cannabinoid system in the pathogenesis and treatment of alcohol dependence]. Postepy Hig Med Dosw (Online) 65:606-615.
125. Stringer RL, Laufer BI, Kleiber ML, Singh SM (2013): Reduced expression of brain cannabinoid receptor 1 (Cnr1) is coupled with an increased complementary micro-RNA (miR-26b) in a mouse model of fetal alcohol spectrum disorders. Clin Epigenetics 5:14.
126. Subbanna S, Psychoyos D, Xie S, Basavarajappa BS (2015): Postnatal ethanol exposure alters levels of 2-arachidonylglycerolmetabolizing enzymes and pharmacological inhibition of monoacylglycerol lipase does not cause neurodegeneration in neonatal mice. J Neurochem 134:276-287.
127. Dasmahapatra AK, Khan IA (2015): Gene-specific disruption of endocannabinoid receptor 1 (cnr1a) by ethanol probably leads to the development of fetal alcohol spectrum disorder (FASD) phenotypes in Japanese rice fish (Oryzias latipes) embryogenesis. Comp Biochem Physiol C Toxicol Pharmacol 167:90-100.
128. Subbanna S, Shivakumar M, Psychoyos D, Xie S, Basavarajappa BS (2013): Anandamide-CB1 receptor signaling contributes to postnatal ethanol-induced neonatal neurodegeneration, adult synaptic, and memory deficits. J Neurosci 33:6350-6366.
129. Faden VB, Graubard BI (2000): Maternal substance use during pregnancy and developmental outcome at age three. J Subst Abuse 12:329-340.
130. Corradi RB (2011): Schizophrenia as a human process. J Am Acad Psychoanal Dyn Psychiatry 39:717-736.
131. Bossong MG, Niesink RJ (2010): Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabisinduced schizophrenia. Prog Neurobiol 92:370-385.
132. Elvevag B, Goldberg TE (2000): Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14:1-21.
133. Spear LP (2000): The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24:417-463.
134. Spear LP, Brake SC (1983): Periadolescence: Age-dependent behavior and psychopharmacological responsivity in rats. Dev Psychobiol 16:83-109.
135. Luna B, Garver KE, Urban TA, Lazar NA, Sweeney JA (2004): Maturation of cognitive processes from late childhood to adulthood. Child Dev 75:1357-1372.
136. Kalsbeek A, Voorn P, Buijs RM, Pool CW, Uylings HB (1988): Development of the dopaminergic innervation in the prefrontal cortex of the rat. J Comp Neurol 269:58-72.
137. Rosenberg DR, Lewis DA (1994): Changes in the dopaminergic innervation of monkey prefrontal cortex during late postnatal development: A tyrosine hydroxylase immunohistochemical study. Biol Psychiatry 36:272-277.
138. Teicher MH, Barber NI, Gelbard HA, Gallitano AL, Campbell A, Marsh E, Baldessarini RJ (1993): Developmental differences in acute nigrostriatal and mesocorticolimbic system response to haloperidol. Neuropsychopharmacology 9:147-156.
139. Bourgeois JP, Goldman-Rakic PS, Rakic P (1994): Synaptogenesis in the prefrontal cortex of rhesus monkeys. Cereb Cortex 4:78-96.
140. Freund TF, Buzsáki G (1996): Interneurons of the hippocampus. Hippocampus 6:347-470.
141. Cruz DA, Weaver CL, Lovallo EM, Melchitzky DS, Lewis DA (2009): Selective alterations in postsynaptic markers of chandelier cell inputs to cortical pyramidal neurons in subjects with schizophrenia. Neuropsychopharmacology 34:2112-2124.
142. Behrens MM, Sejnowski TJ (2009): Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology 57:193-200.
143. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987): Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483-1486.
144. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002): Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 325:1212-1213.
145. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002): Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 156:319-327.
146. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002): Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ 325:1199.
147. Estrada G, Fatjo-Vilas M, Munoz MJ, Pulido G, Minano MJ, Toledo E, et al. (2011): Cannabis use and age at onset of psychosis: Further evidence of interaction with COMT Val158Met polymorphism. Acta Psychiatr Scand 123:485-492.
148. Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, Volk DW, et al. (2008): Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 13:147-161.
149. Zamberletti E, Beggiato S, Steardo L Jr, Prini P, Antonelli T, Ferraro L, et al. (2014): Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. Neurobiol Dis 63:35-47.
150. Prescot AP, Renshaw PF, Yurgelun-Todd DA (2013): gamma-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers. Drug Alcohol Depend 129:232-239.
151. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014): Biological insights from 108 schizophreniaassociated genetic loci. Nature 511:421-427.
152. Morita Y, Ujike H, Tanaka Y, Uchida N, Nomura A, Ohtani K, et al. (2005): A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neurosci Lett 376:182-187.
153. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, et al. (2002): CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7: 515-518.
154. Krebs MO, Morvan Y, Jay T, Gaillard R, Kebir O (2014): Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students. Mol Psychiatry 19:402-403.
155. Bromberg KD, Ma'ayan A, Neves SR, Iyengar R (2008): Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth. Science 320:903-909.
156. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, et al. (2012): Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72: 811-816.
157. Davis KL, Kahn RS, Ko G, Davidson M (1991): Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148:1474-1486.
158. Saez TM, Aronne MP, Caltana L, Brusco AH (2014): Prenatal exposure to the CB1 and CB2 cannabinoid receptor agonist WIN 55, 212-2 alters migration of early-born glutamatergic neurons and GABAergic interneurons in the rat cerebral cortex. J Neurochem 129: 637-648.
159. Scherr M, Hamann M, Schwerthoffer D, Frobose T, Vukovich R, Pitschel-Walz G, Bäuml J (2012): Environmental risk factors and their impact on the age of onset of schizophrenia: Comparing familial to non-familial schizophrenia. Nord J Psychiatry 66:107-114.
160. Rethelyi JM, Benkovits J, Bitter I (2013): Genes and environments in schizophrenia: The different pieces of a manifold puzzle. Neurosci Biobehav Rev 37:2424-2437.
161. Cannon M, Clarke MC (2005): Risk for schizophrenia-broadening the concepts, pushing back the boundaries. Schizophr Res 79: 5-13.
162. Magloczky Z, Freund TF (2005): Impaired and repaired inhibitory circuits in the epileptic human hippocampus. Trends Neurosci 28: 334-340.
163. Hill TD, Cascio MG, Romano B, Duncan M, Pertwee RG, Williams CM, et al. (2013): Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 170:679-692.
164. Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, et al. (2012): Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 21:344-352.
165. Hofmann ME, Frazier CJ (2013): Marijuana, endocannabinoids, and epilepsy: Potential and challenges for improved therapeutic intervention. Exp Neurol 244:43-50.
166. Chesher GB, Jackson DM (1974): Anticonvulsant effects of cannabinoids in mice: Drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia 37: 255-264.
167. Hegde M, Santos-Sanchez C, Hess CP, Kabir AA, Garcia PA (2012): Seizure exacerbation in two patients with focal epilepsy following marijuana cessation. Epilepsy Behav 25:563-566.
168. Cherubini E, Gaiarsa JL, Ben-Ari Y (1991): GABA: An excitatory transmitter in early postnatal life. Trends Neurosci 14:515-519.
169. Leinekugel X, Khazipov R, Cannon R, Hirase H, Ben-Ari Y, Buzsaki G (2002): Correlated bursts of activity in the neonatal hippocampus in vivo. Science 296:2049-2052.
170. McLean HA, Caillard O, Khazipov R, Ben-Ari Y, Gaiarsa JL (1996): Spontaneous release of GABA activates GABAB receptors and controls network activity in the neonatal rat hippocampus. J Neurophysiol 76:1036-1046.
171. Bernard C, Milh M, Morozov YM, Ben-Ari Y, Freund TF, Gozlan H (2005): Altering cannabinoid signaling during development disrupts neuronal activity. Proc Natl Acad Sci U S A 102:9388-9393.
172. Clancy B, Darlington RB, Finlay BL (2001): Translating developmental time across mammalian species. Neuroscience 105:7-17.
173. Mereu G, Fa M, Ferraro L, Cagiano R, Antonelli T, Tattoli M, et al. (2003): Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proc Natl Acad Sci U S A 100: 4915-4920.
174. Szasz A, Barna B, Szupera Z, De Visscher G, Galbacs Z, Kirsch- Volders M, Szente M (1999): Chronic low-dose maternal exposure to methylmercury enhances epileptogenicity in developing rats. Int J Dev Neurosci 17:733-742.
175. Marsh DO, Clarkson TW, Cox C, Myers GJ, Amin-Zaki L, Al-Tikriti S (1987): Fetal methylmercury poisoning. Relationship between concentration in single strands of maternal hair and child effects. Arch Neurol 44:1017-1022.
176. Azadi A, Dildy GA 3rd (2008): Universal screening for substance abuse at the time of parturition. Am J Obstet Gynecol 198:e30-e32.
177. Ostrea EM Jr, Brady M, Gause S, Raymundo AL, Stevens M (1992): Drug screening of newborns by meconium analysis: A large-scale, prospective, epidemiologic study. Pediatrics 89:107-113.
178. Velisek L, Stanton PK, Moshe SL, Vathy I (2000): Prenatal morphine exposure enhances seizure susceptibility but suppresses long-term potentiation in the limbic system of adult male rats. Brain Res 869: 186-193.
179. Baraban SC, McCarthy EB, Schwartzkroin PA (1997): Evidence for increased seizure susceptibility in rats exposed to cocaine in utero. Brain Res Dev Brain Res 102:189-196.
180. Baraban SC, Schwartzkroin PA (1997): Effects of prenatal cocaine exposure on the developing hippocampus: Intrinsic and synaptic physiology. J Neurophysiol 77:126-136.
181. Navarro HA, Howard JL, Pollard GT, Carroll FI (2009): Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol 156:1178-1184.
182. Porter BE, Jacobson C (2013): Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 29:574-577.
183. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. (1980): Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175-185.
184. Mechoulam R, Parker LA, Gallily R (2002): Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol 42:11S-19S.
185. Elphick MR, Egertova M (2001): The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 356:381-408.
186. Kandel DB (2002): Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis. New York: Cambridge University Press.
187. Kandel DB (1984): Marijuana users in young adulthood. Arch Gen Psychiatry 41:200-209.
188. Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, et al. (2005): The endocannabinoid system drives neural progenitor proliferation. FASEB J 19:1704-1706.
189. Aguado T, Palazuelos J, Monory K, Stella N, Cravatt B, Lutz B, et al. (2006): The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci 26:1551-1561.
190. Palazuelos J, Ortega Z, Diaz-Alonso J, Guzman M, Galve-Roperh I (2012): CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling. J Biol Chem 287:1198-1209.
191. Galve-Roperh I, Chiurchiu V, Diaz-Alonso J, Bari M, Guzman M, Maccarrone M (2013): Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog Lipid Res 52:633-650.